Ansell (ASX:ANN) share price gains despite profits tumbling 27% in 'challenging' half

The first half was a tough slog for the personal safety and protection equipment manufacturer.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Ansell share price opened slightly lower before boosting upwards after the release of the company's first half earnings 
  • The company has met its recently slashed sales guidance, with its earnings per share, dividend, and profits all falling between 26% and 27%
  • The disappointing performance was driven by COVID-19 challenges and lower demand

The Ansell Limited (ASX: ANN) share price is in the green on Tuesday after the company released its earnings for the first half of financial year 2022.

At the time of writing, the Ansell share price is $25.92, 0.64% higher than its previous close.

Ansell share price higher despite disappointing first half

  • The company saw around US$1 billion of sales over the half year – a 7.6% increase on the prior comparable period
  • Its earnings before interest and tax (EBIT) came to US$111 million – down 24.3%
  • The company's profits for the half year slipped 27% to US$77.6 million
  • Ansell reported 60.6 US cents of earnings per share (EPS), representing a 26.5% drop
  • Its operating cash flow came to US$22.1 million
  • The company announced an interim dividend of 24.25 US cents per share – a 26% drop on its previous interim dividend

Over the 6 months ended 31 December 2021, the personal safety and protection equipment manufacturer saw its sales grow despite increased challenges.

The company said its overall EBIT margins fell to 11% due to the performance of its healthcare global business unit. The unit saw its own EBITA margin drop by 820 basis points to 10.1% on softer demand.

Ansell's operating cash flow was weaker due to a drop in profitability, employee costs for financial year 2021, and an increase in working capital.

The company's manufacturing operations in South East Asia were hit by COVID-19-induced lockdowns early in the half.

Following the lockdowns, the company found itself facing a labour shortage and logistical delays, contributing to increased backorders for some products.

Its 24.25 US cents interim dividend represents a payout ratio of around 40%, consistent with Ansell's dividend policy.

It ended the first half with US$382.1 million in debt and US$182.9 million of cash and equivalents.

What else happened during the half?

The company's healthcare global business unit's sales for the first half came to US$632.1 million – 15% more than during the first half of financial year 2021. It saw organic growth in all its strategic business units.

However, its Exam/Single Use unit outsourced products' sales volumes dropped due to increased supply and third parties apparently reducing inventory levels.  

Selling high-cost inventory from outsourced suppliers at lower margins, COVID-19 related manufacturing disruptions, higher freight costs, and the company's share of loss from Careplus joint venture were key drivers for EBIT margins' fall.

Meanwhile, Ansell's industrial global business unit saw US$377.1 million of sales over the half – 2.8% lower than the prior comparable period.

The business' Mechanical unit grew 3.2% while its Chemical unit's growth slumped 10.9%.

What did management say?

Ansell managing director and CEO Neil Salmon commented on the half year just gone, saying:

Ansell's [financial year 2022] first half results were delivered in a challenging external environment…

Even in this challenging and complex operating environment we have made significant progress against the most important longer-term drivers of value creation. We are seeing strong interest in new products that address important unmet safety needs, we are winning new customers for our more differentiated product lines, and we are seeing continued strong growth in emerging markets.

Sales growth was encouraging across most of our portfolio as we successfully executed on our long-term strategic plans.

Surgical and Life Sciences grew above market rates showing the benefit of some important new business wins.

Mechanical achieved respectable growth in a mixed industrial demand environment, delivering very strong results in emerging markets and success with new products.

What's next?

As market watchers might have noticed, Ansell dropped its financial year 2022 guidance late last month to the detriment of its share price.

It now expects to provide between 125 US cents and 145 US cents of EPS for financial year 2022.

That assumes sales growth for its Industrial and Surgical and Life Sciences businesses for the second half due to higher production and a seasonal sales increase.

It also assumes that the company's Exam/Single Use unit will see a drop in sales in the second half but that its prices will stay above pre-COVID-19 levels.

Finally, it assumes outsourced supplier costs will continue to fall.

Ansell share price snapshot

The Ansell share price has tumbled into 2022.

It has fallen 21% year to date. The drop can mostly be attributed to the 14% plunge experienced after the company downgraded its guidance.

The Ansell share price is also 32% lower than it was this time last year.

Should you invest $1,000 in Bendigo And Adelaide Bank Limited right now?

Before you buy Bendigo And Adelaide Bank Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Bendigo And Adelaide Bank Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Earnings Results

Why is the QBE share price racing ahead of the benchmark on Friday?

Investors are bidding up QBE shares today. But why?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

Macquarie share price leaps higher on rising full-year profits

Macquarie reported its full year FY 2025 results today. Here's why ASX investors are reacting enthusiastically.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Technology Shares

Guess which ASX 200 tech stock is crashing 14% on results day

This tech stock is having a rough time today. But why?

Read more »

Worried woman calculating domestic bills.
Earnings Results

ANZ share price falls on half-year results

How did the bank perform during the first half? Let's find out.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Bank Shares

NAB share price jumps on solid half year results

Investors have responded positively to the bank's results.

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Earnings Results

Westpac share price sinks on half-year results miss

Let's see how the big four bank performed during the first half.

Read more »

Miner looking at a tablet.
Gold

Newmont share price lifts off on first-quarter results

The ASX 200 gold stock is charging higher on Thursday.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »